Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
3.
Ter Arkh ; 60(11): 29-32, 1988.
Artigo em Russo | MEDLINE | ID: mdl-3238572

RESUMO

The therapeutic effectiveness of interferon inducers (prodigiozan and ibuprofen), the Soviet drug reaferon and their combined use in acute viral hepatitis type B was studied. Indications for their use resulted from lowered capacity of the body for interferonogenesis at the height of the disease. The above drugs stimulated cellular immunity, promoted more rapid disappearance of clinical symptoms of disease, and reduced the period of hospital treatment. A more marked therapeutic effect was noted in combined administration of reaferon and ibuprofen.


Assuntos
Hepatite B/tratamento farmacológico , Indutores de Interferon/uso terapêutico , Interferon Tipo I/uso terapêutico , Doença Aguda , Adolescente , Adulto , Idoso , Formação de Anticorpos/efeitos dos fármacos , Avaliação de Medicamentos , Quimioterapia Combinada , Hepatite B/imunologia , Humanos , Ibuprofeno/efeitos adversos , Ibuprofeno/uso terapêutico , Imunidade Celular/efeitos dos fármacos , Indutores de Interferon/efeitos adversos , Interferon Tipo I/efeitos adversos , Interferon alfa-2 , Interferon-alfa , Pessoa de Meia-Idade , Prodigiozan/efeitos adversos , Prodigiozan/uso terapêutico , Proteínas Recombinantes
7.
Antibiotiki ; 24(8): 632-5, 1979 Aug.
Artigo em Russo | MEDLINE | ID: mdl-485115

RESUMO

High efficacy of prodigiozan, a bacterial polysaccharide used in the form of inhalation in combined therapy of 123 children at the age of 3 to 14 with nonspecific bronchopulmonary pathologic conditions was shown. The drug was administered by means of inhalators UI-I and PAI-I once every 4--5 days in the form of 0.02 per cent solution prepared in situ. The single and the course doses were 100--400 and 300--2000 micrograms respectively. The positive therapeutic effect was observed in 85.0 per cent of the patients: improvement of the patient state was registered 4--6 days earlier than that in the control group, the indices of the respiration mechanics and nonspecific immunity (titers of lysozyme and complement) also improved. The rate of viral respiratory diseases among the children treated with prodigiozan decreased 2.5 times. High efficacy and physiological character of the aerosol method for administration of prodigiozan used the the first time in pediatry provided its recommendation for wide use.


Assuntos
Polissacarídeos Bacterianos/administração & dosagem , Prodigiozan/administração & dosagem , Doenças Respiratórias/tratamento farmacológico , Adolescente , Aerossóis , Bronquite/tratamento farmacológico , Broncopneumonia/tratamento farmacológico , Criança , Pré-Escolar , Doença Crônica , Avaliação de Medicamentos , Estudos de Avaliação como Assunto , Humanos , Pneumonia/tratamento farmacológico , Prodigiozan/efeitos adversos , Recidiva
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...